# Jade Biosciences, Inc. (JBIO) — capital_raise/public_offering [announced]
Source: SEC API (secapi.ai) · situation sit_208cdebcb86c2c0f322e · retrieved 2026-08-14T01:24:11.123Z

## Overview
Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, with lead candidate JADE101 (anti-APRIL monoclonal antibody) in development for immunoglobulin A nephropathy.

Jade Biosciences, Inc. completed a $172.5 million public offering of common stock. The company stated that this offering, combined with its existing cash, cash equivalents, and investments of $461.2 million as of June 30, 2026, is expected to provide runway into the fourth quarter of 2028 to fund its operating expenses and capital expenditure requirements.

## Terms
- Deal value: $172.5M · Consideration: stock

## Key dates
- Announced 2026-08-10

## Timeline
- 2026-08-10 · 8-K (0001193125-26-341229): 8-K - Jade Biosciences, Inc. — *Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, with lead candidate JADE101 (anti-APRIL monoclonal antibody) in development for immunoglobulin A nephropathy.* Jade Biosciences, Inc. completed a $172.5 million public offering of common stock. The company stated that this offering, combined with its existing cash, cash equivalents, and investments of $461.2 million as of June 30, 2026, is expected to provide runway into the fourth quarter of 2028 to fund its operating expenses and capital expenditure requirements.
  https://www.sec.gov/Archives/edgar/data/1798749/0001193125-26-341229.txt

## Citations
- 0001193125-26-341229 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526341229